These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 16943401)

  • 1. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib for the prevention of sporadic colorectal adenomas.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
    N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
    N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
    Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
    Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
    N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial of aspirin to prevent colorectal adenomas.
    Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
    N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
    Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
    Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
    Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
    N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
    Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
    Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
    Baron JA; Beach M; Mandel JS; van Stolk RU; Haile RW; Sandler RS; Rothstein R; Summers RW; Snover DC; Beck GJ; Bond JH; Greenberg ER
    N Engl J Med; 1999 Jan; 340(2):101-7. PubMed ID: 9887161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
    Hawk E; Viner JL
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group.
    Schatzkin A; Lanza E; Corle D; Lance P; Iber F; Caan B; Shike M; Weissfeld J; Burt R; Cooper MR; Kikendall JW; Cahill J
    N Engl J Med; 2000 Apr; 342(16):1149-55. PubMed ID: 10770979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
    Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
    Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.